Wedbush analyst Liana Moussatos reiterated a Buy rating on Catabasis Pharmaceuticals (CATB) today and set a price target of $19. The company’s shares opened today at $4.80, close to its 52-week low of $3.60.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.4% and a 33.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Global Blood Therapeutics.
Catabasis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $52.50.
See today’s analyst top recommended stocks >>
Based on Catabasis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.68 million. In comparison, last year the company had a GAAP net loss of $5.5 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catabasis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of therapeutics for the treatment of cardiovascular, metabolic and inflammatory diseases.
